BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21770016)

  • 1. Changing picture of central nervous system complications in liver transplant recipients.
    Vizzini G; Asaro M; Miraglia R; Gruttadauria S; Filì D; D'Antoni A; Petridis I; Marrone G; Pagano D; Gridelli B
    Liver Transpl; 2011 Nov; 17(11):1279-85. PubMed ID: 21770016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
    Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
    Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The possible causes of serious central nervous system complications occurring after liver transplantation].
    Li FQ; Li B; Yan LN; Zeng Y; Wen TF; Zhao JC; Zhang ZW; Liu XL; Yang M; Zhang GT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):535-8. PubMed ID: 17593851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.
    Farges O; Saliba F; Farhamant H; Samuel D; Bismuth A; Reynes M; Bismuth H
    Hepatology; 1996 Feb; 23(2):240-8. PubMed ID: 8591847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience.
    Xu X; Ling Q; He ZL; Gao F; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):465-70. PubMed ID: 18842490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukoencephalopathy syndrome after living-donor liver transplantation.
    Umeda Y; Matsuda H; Sadamori H; Shinoura S; Yoshida R; Sato D; Utsumi M; Yagi T; Fujiwara T
    Exp Clin Transplant; 2011 Apr; 9(2):139-44. PubMed ID: 21453233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. University of Modena experience in HIV-positive patients undergoing liver transplantation.
    Di Benedetto F; Tarantino G; De Ruvo N; Cautero N; Montalti R; Guerrini GP; Ballarin R; Spaggiari M; Smerieri N; Serra V; Rompianesi G; D'Amico G; Mimmo A; Iemmolo RM; Codeluppi M; Cocchi S; Guaraldi G; Gerunda GE
    Transplant Proc; 2011 May; 43(4):1114-8. PubMed ID: 21620066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN; Mela M; Quaglia A; Triantos CK; Thalheimer U; Leandro G; Pesci A; Raimondo ML; Dhillon AP; Rolles K; Davidson BR; Patch DW; Burroughs AK
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
    Balderramo D; Prieto J; Cárdenas A; Navasa M
    Transpl Int; 2011 Aug; 24(8):812-9. PubMed ID: 21649743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
    Forgacs B; Merhav HJ; Lappin J; Mieles L
    Transplant Proc; 2005 May; 37(4):1912-4. PubMed ID: 15919502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurological complications following a liver transplantation: experience from a Chilean center].
    Mellado P; Peredo P; Valenzuela R; Arrese M; Pérez RM; Domínguez P; Guerra JF; Jarufe N; Martínez J
    Rev Med Chil; 2008 Oct; 136(10):1255-63. PubMed ID: 19194621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute renal failure after cadaveric related liver transplantation.
    Chuang FR; Lin CC; Wang PH; Cheng YF; Hsu KT; Chen YS; Lee CH; Chen CL
    Transplant Proc; 2004 Oct; 36(8):2328-30. PubMed ID: 15561239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants.
    Singh N; Gayowski T; Wagener M; Yu VL
    Transplantation; 1994 Oct; 58(7):774-8. PubMed ID: 7524204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.